The FDA accepted an NDA for a bictegravir and lenacapavir single-tablet regimen for adults with HIV-1 who have achieved virologic suppression.
Abstract: Testing of spin-based quantum devices is currently performed through quantum dot and qubit measurements at deep cryogenic temperatures, well below 1 K. At such low temperatures, the testing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results